Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Wells:2020:10.1016/S2213-2600(20)30036-9,
author = {Wells, AU and Flaherty, KR and Brown, KK and Inoue, Y and Devaraj, A and Richeldi, L and Moua, T and Crestani, B and Wuyts, WA and Stowasser, S and Quaresma, M and Goeldner, R-G and Schlenker-Herceg, R and Kolb, M},
doi = {10.1016/S2213-2600(20)30036-9},
journal = {LANCET RESPIRATORY MEDICINE},
pages = {453--460},
title = {Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial},
url = {http://dx.doi.org/10.1016/S2213-2600(20)30036-9},
volume = {8},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Wells,AU
AU  - Flaherty,KR
AU  - Brown,KK
AU  - Inoue,Y
AU  - Devaraj,A
AU  - Richeldi,L
AU  - Moua,T
AU  - Crestani,B
AU  - Wuyts,WA
AU  - Stowasser,S
AU  - Quaresma,M
AU  - Goeldner,R-G
AU  - Schlenker-Herceg,R
AU  - Kolb,M
DO  - 10.1016/S2213-2600(20)30036-9
EP  - 460
PY  - 2020///
SN  - 2213-2600
SP  - 453
TI  - Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
T2  - LANCET RESPIRATORY MEDICINE
UR  - http://dx.doi.org/10.1016/S2213-2600(20)30036-9
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000531069600033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 8
ER  -
Download